ERBB2 and breast cancer: While this finding itself does not justify the use of trastuzumab monotherapy across all T1N0 HER2 + BC patients (given the limitations of retrospective analysis), it does warrant further investigation into how chemotherapy-free regimens could be applied to risk-stratified patients within this population.